Introduction
Follicular lymphoma is the most frequent indolent lymphoma and accounts for approximately 20-30% of all malignant lymphomas in adults. 1 The course of follicular lymphoma is quite variable, with some patients followed expectantly for many years without needing therapy and others having a much more aggressive course with rapid progression, early relapses and eventual transformation to aggressive histology. [2] [3] [4] Follicular lymphoma remains incurable with conventional treatment modalities and thus the main indication for treatment is the alleviation of disease-related symptoms. Although most patients achieve CR or PR following initial chemotherapy (CT), relapse is inevitable. The addition of rituximab to induction CT followed by 2 years of rituximab maintenance significantly prolongs PFS and OS, and has become the current standard initial therapy for follicular lymphoma. 5 As there is no universally accepted standard therapy for relapsed follicular lymphoma, patients and their physicians must choose between treatment options that differ substantially in terms of effectiveness and tolerability. Treatment options for relapsed follicular lymphoma include repeated cycles of conventional CT, radioimmunotherapy (RIT) using a radiolabeled anti-CD20 B-cell Ab, high-dose therapy with auto-SCT or allo-SCT. Fludarabine-based conventional dose CT regimens are associated with high response rates (450%), however, the majority of patients relapse within 1-2 years of treatment. [6] [7] [8] RIT provides targeted total body radiation treatment that is well tolerated, provides long-term disease control in 10-15% of patients, but is associated with median remission durations of B1 year. [9] [10] [11] [12] Both auto-SCT and allo-SCT are only appropriate for younger, fit patients. Auto-SCT confers a significant PFS benefit over conventional CT, however, B50% of patients will relapse within 5 years. 13, 14 Allo-SCT is generally accepted to have curative potential for follicular lymphoma and is associated with a markedly reduced relapse rates (B20%), but at the expense of higher treatment-related mortality (B30%), thus resulting in similar OS rates when compared to auto-SCT. 15 Choice between treatment options requires consideration of the goals of therapy (palliative vs prolongation of survival), performance status, previous type of therapy and best response to past therapy. No objective data exist regarding physician or patient preference for these treatment options, nor on which factors affect these preferences. The discrete choice experiment (DCE) is a method that can be used to elicit preference and has been applied in healthcare research. [16] [17] [18] [19] The health-care intervention being valued must be described in terms of characteristics or attributes. In a multiple choice experiment, individuals are presented with a series of choice sets, described in terms of relevant attributes and associated levels, and are asked to make their preferred choice. Logit or probit regression analysis yields information about the importance and direction of influence of each attribute on choice. Furthermore, how individuals trade between attributes, comparison of interventions according to overall utility or willingness to pay, probability of choosing an intervention and attribute level required to achieve a certain probability of choosing an intervention are all estimable outcomes.
The purpose of this study was to elicit preference, using a DCE, for distinct treatment options used for relapsed follicular lymphoma, and their associated attributes, amongst patients in Alberta as well as hematologists and medical oncologists who treat lymphoma in Canada.
Methods

Study population
Eligible patients were those between the ages of 18 and 65, diagnosed with follicular lymphoma, who had received treatment for follicular lymphoma at the Alberta Cancer Centre between 2002-2006 and were able to read and write in English. Potential patient participants were identified through the Alberta Cancer Board Electronic Medical Record. A total of 180 eligible patients were sent a letter inviting them to participate. Interested patients were asked to return a signed letter of consent before receiving further communication regarding the study. Eligible physicians included hematologists and medical oncologists registered with the Royal College of Physicians and Surgeons of Canada (RCPSC). Medical oncologists who treat lymphoma in Canada were identified from attendance at the National Cancer Institute of Canada Hematology Site Meetings. A total of 252 physicians were potentially eligible for this study, although it was not possible to identify which hematologists were still practicing medicine, who treated lymphoma or who had changed addresses from the RCPSC records. No financial or other incentive was provided to any participants. Local scientific and ethical approval was obtained from the Conjoint Health Research Ethics Board in Calgary, Alberta, Canada, prior to study initiation.
Sample size
Theoretical formulae for calculating sample size of a DCE have been proposed, but are not readily applicable. A reported heuristic is that 50 respondents are required to allow estimation of a reliable choice model consisting of main effects only. 20 Hence, for this study, a minimum of 50 patients and 50 physicians was desired in order to be able to analyze the separate groups.
Questionnaire
The questionnaire contained background information (a brief overview of follicular lymphoma, current treatment options and information about the study), the DCE, questions addressing participant demographics including personal clinical information for patients and a selfaddressed stamped return envelope. A reminder postcard was sent 4 weeks after the initial mailing to those who had not yet responded to the survey. Contact information was provided to allow for participants to address any questions or difficulties with completing the questionnaire. Demographic and clinical information, such as age, gender, education, annual income, date of follicular lymphoma diagnosis, disease status and treatments to date, were obtained from patients who completed the survey. Physician demographic and practice information were also collected and that included age, gender, region of practice within Canada, years in clinical practice, percentage of practice that involves lymphoma and whether practice involves SCT. Descriptive statistics was applied to participant demographic and clinical data. Owing to the small sample size, subgroup analyses within patient or physician groups were not planned or considered appropriate.
Background information provided to participants included lay descriptions of follicular lymphoma, the slow growing remitting-relapsing nature of the disease, differing goals of treatment such as decreasing symptoms, slowing tumor growth or prolonging survival, and the issue of disease relapse. It was explained to participants that this study would help understand how they weigh the potential risks and benefits associated with second-line treatments of follicular lymphoma.
From the DCE, we wanted to obtain preference information pertaining to the four major treatment options for relapsed follicular lymphoma: standard CT, RIT, highdose therapy and auto-SCT, and allo-SCT. The level for each attribute for individual treatment options was determined by reviewing the current literature on secondand third-line treatment options for patients with relapsed follicular lymphoma (Table 1) . [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] As shown, the attributes included administration protocol, toxicity of the regimen, survival free of relapse and cost. Four categorical levels were used to describe the various administration protocols and toxicities for each treatment option. Current Alberta provincial treatment guidelines recommend that the majority of advance stage follicular lymphoma patients receive R-CVP (rituximab, CY, VCR, prednisone) followed by rituximab maintenance as initial therapy. A fludarabinebased regimen, FND (fludarabine, mitoxantrone, dexamethasone), was selected upon which to model the second-line CT treatment option. Second-line therapy with FND is potentially non-cross-resistant to R-CVP/rituximab maintenance and the choice of FND was based on established efficacy and common usage in relapsed follicular lymphoma. 6, 8 Survival free of relapse was described in terms of median remission length (PFS in years) and chances of being alive without progressive disease 5 years after treatment (that is, 5-year PFS). In our study preamble, we described cost as that which is footed by the health-care system and not as an out-of-pocket cost. Four numerical levels were chosen to reflect current healthcare system expenditures: $5000 (CT), $25 000 (RIT), $50 000 (auto-SCT) and $150 000 (allo-SCT).
Given three attributes with four levels and one attribute with two levels, 128 profiles were possible. A fractional factorial design was chosen to examine the main effects only. A total of 16 choices were required and a matched, fold-over technique was used to create choice sets. As a test of internal consistency, an additional dominant choice set was added (one profile presented superior levels on all attributes). The 17 choice sets were randomly ordered. For each choice set, respondents were asked to choose between two unlabeled treatment options (A or B). An example of a choice set is shown in Table 2 .
Prior to the main study, the DCE questionnaire was independently reviewed for content accuracy and face validity by two members of the Calgary Hematology Tumor Group, and was also examined for face readability and acceptability by a small group of five lymphoma patients and five medical oncologists in Calgary.
Analysis
The DCE was analyzed with random effects logit regression using Intercooled Stata Version 9 (Statacorp., College Station, TX, USA). The dependent variable was choice, whereas independent variables were the attributes and the group variable was respondent. Survival free of relapse (remission length and remission chance) and cost were treated as continuous variables, and the remaining categorical attributes were dummy coded. Statistical significance was considered when the P-value was o0.05.
The important attributes were those with statistically significant coefficients from the regression analysis. For the important attributes, whether each was a positive or negative influence on choice was indicated by the sign of the coefficient. Strength of preference for the important attributes was determined through marginal rate of subtitution calculations using the coefficients from the regression (coefficient on the attribute being valued, divided by coefficient on the attribute being used as a measure of value). A post-estimation technique was used to examine the probability of choosing each of the four treatment options.
Underpinning the DCE method is random utility theory, which states that the utility U, that individual i derives from alternative j, is composed of systematic (V) and random components (e):
The systematic component V is often modeled as a linearly additive function of the attributes:
where X 0 ij is a vector of explanatory variables and b is a conformable vector of coefficients. Explanatory variables are those attributes specific to the intervention or service, but can also include others to describe individual characteristics. However, as utility cannot be directly measured, choice is taken as an indicator. It is assumed that an individual i chooses option 1 if, and only if, its utility is higher than the utility of any other option in the set of j alternatives. The probability that utility is maximized in choosing option 1 is:
where Y i is the dependent variable denoting the choice outcome.
In this DCE, the following analytical model was estimated:
The observable utility derived from treatment is v, the attributes or variables are shown in brackets and b 1 through b 8 represent the attribute coefficients.
Marginal rate of substitution was calculated by taking the coefficient on the attribute being valued over the coefficient on that attribute that is being used as a measure of value. For the example of cost and survival free of remission, the calculation would be b 1 /b 2 . Probability of choosing a treatment was calculated as follows. First, utility scores for the four treatment options were determined using the estimated model (Equation (4)) with substitution of the assigned attribute levels (that is, for RIT: median PFS ¼ 1, cost ¼ 25 000, admin RIT ¼ 1, admin auto-SCT ¼ 0, admin allo-SCT ¼ 0, tox RIT ¼ 1, tox auto-SCT ¼ 0, tox allo-SCT ¼ 0). Second, the utility scores calculated were substituted into Equation (5) below for the different settings of drug availability:
Results
Of the 180 patients who were invited to participate in this study, 98 (54%) consented to the survey and 81 completed the questionnaire, resulting in an overall participation rate of 45%. Table 3 lists the characteristics of the responding patients. The respondents had a mean age of 54.7 years and an average time from diagnosis of 4.4 years. Approximately one half had not experienced a relapse, whereas one-third were symptomatic at the time they completed the questionnaire. Of note, 93% had received prior CT and 24.7% received prior high-dose therapy and SCT, including autologous ¼ 15 (18.5%), allogeneic ¼ 4 (5%), syngeneic ¼ 1 (1.2%).
Of the 252 physicians who were sent a questionnaire, 38 (15%) did not treat lymphoma, 1 declined the survey (0.4%) and 161 did not respond, resulting in an overall participation rate of only 19% (n ¼ 48). Table 4 lists the demographic and practice characteristics of the responding physicians. The mean age of physicians was 43.6 years and their mean time in practice was 12.2 years. Physicians were predominantly hematologists (94%), who worked primarily in Alberta, British Columbia or Ontario. About half of the responding physicians had practices that included SCT. DCE A total of 2193 choices (129 participants Â 17 questions each) were posed in the DCE. Only 18 of the 2193 questions were unanswered across six patients and one physician, resulting in a completion rate of 99.2%, indicating that the questionnaire was not difficult to complete for those who elected to participate in the study. Five patients and no physician failed the dominant choice question, however, their data were retained in the DCE analysis. 21 
Regression analysis
The results of the regression analysis are shown in Table 5 . The Wald Chi-squared with its P-value o0.001 indicates that the model as a whole is statistically significant in that the attributes taken together have an effect on choice. Remission length, cost and toxicity of transplantation (relative to CT) were important attributes as indicated by statistically significant coefficients. The coefficient on remission length was positive for both patients and physicians, indicating that longer remission duration increased the likelihood of choosing a treatment option. When remission chance (5-year PFS) was substituted for remission length (median PFS in years), apart from a different value for the coefficient, the results were identical as expected (data not shown). The coefficient on toxicity of allo-SCT was negative, meaning that the described toxicities corresponding to this treatment in comparison with CT decreased the likelihood of choosing the treatment option. Neither toxicity of RIT nor auto-SCT was significant on influences on choice for either patients or physicians. Cost was an important negative influence on choice only for physicians.
Strength of preference
Strength of preference regarding toxicity of treatment was measured against survival free of relapse. Participants required 0.6 years absolute increase in PFS or a 6% absolute increase in 5-year PFS in order to accept the toxicity of auto-SCT (relative to CT), but 3.9 years increase in PFS or a 39% increase in 5-year PFS in order to accept the toxicity of allo-SCT (relative to CT).
Probability of choosing a treatment
Through the post-estimation technique calculations, the majority of patients favored the option of auto-SCT (69%) followed by RIT (14%), CT (11%) and allo-SCT (7%). The result for physicians was similar, with a majority choosing auto-SCT (56%) followed by RIT (20%), CT (19%) and allo-SCT (4%). Because RIT is not funded in most Canadian provinces, we also evaluated the distribution of preferences without RIT as a choice. When RIT was excluded, the proportion preferring auto-SCT increased for both patients (80% auto-SCT, 12% CT, 8% allo-SCT) and physicians (71% auto-SCT, 24% CT, 5% allo-SCT).
Discussion
Nearly all patients with follicular lymphoma will experience relapse and be faced with decisions about subsequent treatments. This DCE has helped advance the understanding of how patients and physicians make choices about second-line therapy and it has contributed to the DCE literature which focuses on eliciting preference for cancer therapies. For both patients and physicians, survival free of relapse was an important positive influence on choice. Toxicity of allo-SCT relative to standard CT was an important negative influence on choice. It was somewhat surprising that toxicity of RIT relative to standard CT was not a significant positive influence on choice. However, the coefficient was of the expected direction, and a larger sample size may result in statistical significance. Alternatively, as most patients had already been through first-line CT, 'fear' of side effects from second-line CT may have been alleviated. Administration of treatment did not influence the choice in this study. Cost was a significant negative influence on choice only to physicians. This result is not unexpected as health care is publically funded in Alberta and hence, patients are not used to thinking about the related costs. On the other hand, physicians are often involved in the development of practice guidelines, which increasingly may consider economic analyses.
22-24
When strength of preference for toxicity was measured against survival free of relapse, participants required a chance of remission or remission length close to seven times higher for allo-SCT compared with auto-SCT. Clearly, participants placed tremendous value on survival free of relapse and toxicity of allo-SCT when making hypothetical treatment decisions. This is, despite our conservative estimate of treatment-related mortality, associated with allo-SCT. Given the strength of preference results, it was consistent that autologous transplantation was estimated to be the favored treatment option.
Several points can be made in favor of internal validity for this DCE. The questionnaire was examined for content and face validity. Logical and significant results were obtained, and few participants failed the dominant choice question (picked the treatment option with an inferior level for each attribute). Those who answered the questionnaire completed 499% of the questions, strongly suggesting that the questions were adequately understood by patients. In addition, our contact information was included in the information package and questionnaire for those who had difficulty completing the questionnaire. No phone calls were received by patients who could not understand the questionnaire. One can argue that there was probably no good reason to choose allo-SCT based upon higher toxicity but similar PFS as auto-SCT, basically resulting in an internal check of the survey. The fact that subjects rarely chose attributes associated with allo-SCT strongly suggests that they understood the survey. To our knowledge, studies examining actual uptake of the different therapies for relapsed follicular lymphoma have not been reported and hence, we do not have a gold standard with which our estimates can be compared.
The study had several potential limitations. As we did not refer to a specifically defined case, the responses from participants may have varied if certain prognostic factors were altered. For example, if transformed follicular lymphoma was considered, the implications of treatment and outcome would have differed from those of relapsed follicular lymphoma, and could have elicited different preferences. Of the multitudes of salvage CT regimens, FND was chosen, as most patients in Alberta would have been previously treated with rituximab-containing CT, usually R-CVP. There is little evidence to suggest that rituximab in the salvage regimen is substantially more effective than CT alone after a previous failure of rituximab. We did not address other options (for example, bendamustine) or investigational agents in the context of a clinical trial. If less toxic, more effective CT treatments were available, and then this would certainly influence the results and may shift individuals away from auto-SCT. The number of attributes was purposely limited for this DCE, as a higher number of choices produces a longer questionnaire, and concern regarding participation and respondent use of simplifying heuristics arises. 25 One may criticize the study for not including an attribute for the 'curative' potential of allo-SCT, given this treatment is associated with the lowest rates of relapse. The potential for cure was not listed as an attribute for allo-SCT, because a widely accepted definition of cure has not been established for follicular lymphoma, and therefore, good quality data on the frequency of 'cure' or 10-20-year PFS rates following auto-SCT, allo-SCT, FND or RIT do not exist. We based the attributes in the survey on firm published data rather than frequently stated but poorly substantiated beliefs that an allo-SCT offers better chance of long-term PFS than auto-SCT. There are no data supporting this hypothesis from prospective randomized trials. This is particularly the case for patients in first relapse, when an allo-SCT is rarely performed owing to risks of treatmentrelated mortality. As opposed to the lack of published longterm data related to allo-SCT, long-term results beyond 10 years following auto-SCT report plateaus on PFS curves for studies specifically addressing follicular lymphoma patients transplanted prior to third or later relapse. 13, [26] [27] [28] Therefore, issue of 'cure' for follicular lymphoma is controversial, and dramatically increasing the number of required scenarios by adding another attribute to the questionnaire was considered to be unjustified. A 5-year period of PFS was considered to be a reasonable measure of treatment effectiveness for the purpose of this study. It is important to note that the objective of the DCE is not to identify specific treatments, but rather the features associated with each treatment that influence the choice.
Further limitations include the fact that B25% of patients and 54% of physicians had prior experience with SCT, which could have biased their choices for or against 'administration' and 'side-effect' attributes associated with auto-SCT and allo-SCT. Some patients had more than one prior therapy for follicular lymphoma and this too could have influenced the choice. Unfortunately, the small sample size precluded reliable subgroup analysis to further evaluate these issues. The patient population was aged less than the median age of follicular lymphoma, because we only wanted to survey transplant eligible patients and older patients would usually not be considered for auto-SCT or allo-SCT. Our patient population was generally well educated and had moderate-to-high income; factors that may have influenced the likelihood of participation in the study. The response rate of patients was 45%, but for physicians it was only 19%. This low response rate to the survey may imply a selection bias, but in the case of the physicians, it is probable that hematologists who rarely treat follicular lymphoma did not complete the survey.
Although the sample size for physicians was smaller than our intended target, we were still able to show some influence on choice. Finally, although the attribute levels we chose for each treatment (Table 1) were based upon published data, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] these levels were rounded for simplification. Some single center experiences with these treatments may differ slightly from these levels, however, the basic concepts influencing choice would likely remain constant despite minor alterations to specific details in these levels. Of most importance, we were very conservative in the estimation of treatment-related mortality associated with allo-SCT, which may not apply in the modern era of reduced intensity transplantation. In this study, we did not include potential for cure as an attribute for allo-SCT owing to lack of good quality data for long-term results of allo-SCT in relapsed follicular lymphoma. A small proportion of patients will likely accept higher risk of toxicity to obtain higher reward.
The treatment of relapsed follicular lymphoma is quite complex owing to the multitude of available treatment options that continues to grow quite rapidly. Our study has demonstrated that patients are willing to trade-off the toxicity associated with auto-SCT in order to benefit from increased survival free of relapse. The use of auto-SCT varies considerably between Canadian cities, and the results of this study suggest that the use of auto-SCT might increase if the treatment was offered, and attributes associated with this and other treatment options were thoroughly discussed with patients. Our study also confirms that individual patients favor more conservative therapy, while others are willing to take bigger risks associated with allo-SCT. Future research could focus on preference of specific patient subgroups (age, initial remission duration, disease transformation) and different physician subgroups (those who participate in transplantation vs those who do not), or preference for new front-line therapies.
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